MXPA05007583A - Metodo para el tratamiento de cancer de prostata y composicion para dicho tratamiento. - Google Patents
Metodo para el tratamiento de cancer de prostata y composicion para dicho tratamiento.Info
- Publication number
- MXPA05007583A MXPA05007583A MXPA05007583A MXPA05007583A MXPA05007583A MX PA05007583 A MXPA05007583 A MX PA05007583A MX PA05007583 A MXPA05007583 A MX PA05007583A MX PA05007583 A MXPA05007583 A MX PA05007583A MX PA05007583 A MXPA05007583 A MX PA05007583A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- composition
- prostate cancer
- effective amount
- effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Un metodo y composicion para el tratamiento del cancer de prostata que comprende una cantidad efectiva de un antiandrogeno no esteroideo y una cantidad efectiva de un modulador selectivo del receptor de estrogeno. La composicion tiene menores efectos colaterales que la mastodinia y la ginecomastia, y tambien es mas efectiva como una terapia auxiliar para prevenir la reaparicion del cancer de prostata.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44093703P | 2003-01-17 | 2003-01-17 | |
US10/754,308 US7332525B2 (en) | 2003-01-17 | 2004-01-09 | Method of treatment of prostate cancer and composition for treatment thereof |
PCT/US2004/000668 WO2004066962A2 (en) | 2003-01-17 | 2004-01-12 | Method of treatment of prostate cancer and composition for treatment thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05007583A true MXPA05007583A (es) | 2005-09-21 |
Family
ID=32718199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05007583A MXPA05007583A (es) | 2003-01-17 | 2004-01-12 | Metodo para el tratamiento de cancer de prostata y composicion para dicho tratamiento. |
Country Status (8)
Country | Link |
---|---|
US (1) | US7332525B2 (es) |
EP (1) | EP1583536B1 (es) |
JP (1) | JP2007508397A (es) |
KR (1) | KR20050096135A (es) |
AU (1) | AU2004207442B2 (es) |
CA (1) | CA2509390C (es) |
MX (1) | MXPA05007583A (es) |
WO (1) | WO2004066962A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20040096510A1 (en) * | 2001-11-29 | 2004-05-20 | Steiner Mitchell S. | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
EP1789090A2 (en) * | 2004-09-02 | 2007-05-30 | Bionaut Pharmaceuticals, Inc. | Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors |
US20060135442A1 (en) * | 2004-09-02 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors |
US20080027010A1 (en) * | 2004-09-02 | 2008-01-31 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using Na+/K+-ATPase inhibitors |
US20070105790A1 (en) * | 2004-09-02 | 2007-05-10 | Bionaut Pharmaceuticals, Inc. | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors |
US20060135468A1 (en) * | 2004-09-02 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using NA+/K+ ATPase inhibitors |
EP1812010A2 (en) * | 2004-10-18 | 2007-08-01 | BTG International Limited | Use of na+/ k+-atpase inhibitors and antagonists thereof |
DE102005005397B4 (de) * | 2005-02-05 | 2008-08-21 | Lts Lohmann Therapie-Systeme Ag | Isolierung von N-Butylbenzolsulfonamid, Synthese von Benzolsulfonamid-Derivaten sowie Verwendung von N-Butylbenzolsulfonamid und Benzolsulfonamid-Derivaten zur Behandlung der benignen Prostatahyperplasie und/oder des Prostatakarzinoms |
US20080194527A1 (en) * | 2007-02-14 | 2008-08-14 | Tcp Innovations Ltd | Compositions and combinations 2 |
US20110136858A1 (en) * | 2009-12-04 | 2011-06-09 | Grainger David J | Preferred Combination Therapy |
US8501690B2 (en) | 2010-04-30 | 2013-08-06 | John G. Stark | Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue |
PT2785349T (pt) * | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
AU2013205648B2 (en) * | 2011-11-30 | 2015-02-05 | Astrazeneca Ab | Combination treatment |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US114519A (en) * | 1871-05-09 | Improvement in clothes-driers | ||
US36956A (en) * | 1862-11-18 | Improvement in the process of stripping tobacco-leaves | ||
US103141A (en) * | 1870-05-17 | Richard t | ||
US134899A (en) * | 1873-01-14 | Improvement in machines for making boot and shoe heels | ||
US173445A (en) * | 1876-02-15 | Improvement in furnaces for brick-kilns | ||
US76695A (en) * | 1868-04-14 | Improved buttoi-eole lining foe caeeiage-cuetains | ||
US25051A (en) * | 1859-08-09 | Nail-plate feeder | ||
BE637389A (es) * | 1962-09-13 | |||
US3995060A (en) * | 1972-06-20 | 1976-11-30 | Schering Corporation | Antiandrogenic agents and method for the treatment of androgen dependent disease states |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
DE2817157A1 (de) * | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4420483A (en) * | 1982-07-22 | 1983-12-13 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
US5023088A (en) * | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
US5595985A (en) * | 1989-03-10 | 1997-01-21 | Endorecherche Inc. | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia |
US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
KR920703065A (ko) * | 1989-07-07 | 1992-12-17 | 원본미기재 | 안드로겐 관련질병의 치료방법 |
JP3157882B2 (ja) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5593987A (en) * | 1993-12-21 | 1997-01-14 | Eli Lilly And Company | Methods of inhibiting breast disorders |
JPH09508125A (ja) | 1994-01-21 | 1997-08-19 | セプラコー,インコーポレイテッド | 光学的純正r−(−)−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成 |
US6468981B1 (en) * | 1994-07-29 | 2002-10-22 | Emory University | Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US20020076695A1 (en) | 1997-04-04 | 2002-06-20 | Jeffrey S. Ross | Methods for treating prostate cancer |
US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6410043B1 (en) * | 1998-05-07 | 2002-06-25 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
EP1003496B1 (en) * | 1998-05-07 | 2004-11-24 | The University Of Tennessee Research Corporation | Medicament for treating prostate intraepithelial neoplasia |
EP1102755B1 (en) | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
US20020103141A1 (en) | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
WO2000074684A1 (en) * | 1999-06-04 | 2000-12-14 | The General Hospital Corporation | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
US20030114519A1 (en) | 2000-05-23 | 2003-06-19 | Barrington Furr | Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition |
GB0012291D0 (en) | 2000-05-23 | 2000-07-12 | Astrazeneca Ab | Pharmaceutical combination |
MXPA02012605A (es) | 2000-06-28 | 2003-05-14 | Squibb Bristol Myers Co | Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso. |
WO2002002099A1 (en) | 2000-07-05 | 2002-01-10 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition |
WO2002089801A1 (en) * | 2001-05-10 | 2002-11-14 | Cedars Sinai Medical Center | Use of benzothiophenes to treat and prevent prostave cancer |
SE0103839D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
EP1862165A3 (en) * | 2001-11-29 | 2008-06-25 | GTX, Inc. | Prevention and treatment of androgen-deprivation induced hot flashes |
-
2004
- 2004-01-09 US US10/754,308 patent/US7332525B2/en not_active Expired - Fee Related
- 2004-01-12 MX MXPA05007583A patent/MXPA05007583A/es active IP Right Grant
- 2004-01-12 WO PCT/US2004/000668 patent/WO2004066962A2/en active Application Filing
- 2004-01-12 AU AU2004207442A patent/AU2004207442B2/en not_active Ceased
- 2004-01-12 KR KR1020057013114A patent/KR20050096135A/ko not_active Application Discontinuation
- 2004-01-12 JP JP2006536528A patent/JP2007508397A/ja active Pending
- 2004-01-12 EP EP04701509A patent/EP1583536B1/en not_active Expired - Lifetime
- 2004-01-12 CA CA2509390A patent/CA2509390C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2007508397A (ja) | 2007-04-05 |
EP1583536B1 (en) | 2013-03-20 |
EP1583536A2 (en) | 2005-10-12 |
CA2509390A1 (en) | 2004-08-12 |
WO2004066962A2 (en) | 2004-08-12 |
CA2509390C (en) | 2011-07-19 |
AU2004207442B2 (en) | 2008-06-19 |
AU2004207442A1 (en) | 2004-08-12 |
EP1583536A4 (en) | 2009-07-15 |
US7332525B2 (en) | 2008-02-19 |
KR20050096135A (ko) | 2005-10-05 |
US20040142973A1 (en) | 2004-07-22 |
WO2004066962A3 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05007583A (es) | Metodo para el tratamiento de cancer de prostata y composicion para dicho tratamiento. | |
AU2003293194A8 (en) | Compositions and methods for treating prostate cancer | |
EP1690323A4 (en) | METHOD FOR MODULATING LASER ACCELERATED PROTONS FOR RADIATION THERAPY | |
HUP0203304A3 (en) | Method and composition for chemoprevention of prostate cancer | |
AU2003302892A8 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
SG148864A1 (en) | Methods of treating cancer and related methods | |
AU2003291356A8 (en) | Methods and compositions for treating cancer using proteasome inhibitors | |
AU2003267203A8 (en) | Method for administering thermotherapy to prevent the growth of tumors | |
SI1255537T1 (sl) | Inhibitorji farnezil protein transferaze za zdravljenje raka dojk | |
AU2003232882A8 (en) | Prostacyclin derivatives for treating cancer | |
IL175974A (en) | Radiation protection plugins | |
AU2002340168A1 (en) | Treatment of prostate cancer by inhibitors of ncam2 | |
MXPA03003632A (es) | Metodo para tratamiento de tumores usando terapia de combinacion. | |
IL147748A0 (en) | Use of etodolac to treat cancer | |
TR200101693T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
AP9801261A0 (en) | Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer. | |
AU2003302822A8 (en) | Antibodies to treat cancer | |
EP1596806A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IGSF9 AND LIV-1 | |
AU2003241346A8 (en) | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer | |
AU2003298708A8 (en) | Gpc99 and gpc99a: methods and compositions for treating cancer | |
IL164218A0 (en) | Use of interleukin-19 to treat ovarian cancer | |
IL150978A0 (en) | Nitroacridine/tumor inhibitor compositions | |
AU2292801A (en) | Compositions and methods for treatment of breast cancer | |
EP1646385A4 (en) | USE OF BENZOTHIOPHENES TO TREAT AND PREVENT PROSTATE CANCER | |
WO2005048956A3 (en) | Estradiol-related compounds and methods of use as anti-tumor agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |